Frances A. Shepherd

Frances A. Shepherd, MD, FRCPC, is an Emerita Professor of Medicine and Senior Staff Physician at Princess Margaret Cancer Centre and the University of Toronto, and one of the most celebrated clinical trialists in the history of lung cancer medicine. Her career spans more than four decades of clinical research that has helped define the standard of care for both non-small cell and small cell lung cancer. She led or co-led numerous landmark studies—including the BR.21 trial of erlotinib in previously treated NSCLC and the JBR.10 trial of adjuvant vinorelbine plus cisplatin—that have been cited thousands of times and have fundamentally shaped international practice guidelines. Shepherd's contributions to adjuvant chemotherapy for early-stage NSCLC, through the National Cancer Institute of Canada (NCIC) Clinical Trials Group JBR.10 trial, provided definitive evidence that cisplatin-based adjuvant chemotherapy improves overall survival following complete resection, establishing adjuvant therapy as standard care for resected stage II–III NSCLC. Her leadership of BR.21 demonstrated a significant overall survival benefit for erlotinib over placebo as second/third-line therapy for advanced NSCLC, contributing to the first approval of an EGFR inhibitor in an unselected NSCLC population. She has also led pivotal studies in small cell lung cancer and contributed to standards for maintenance therapy and second-line treatment in NSCLC. Over her career, Shepherd has received the highest honors in oncology and has mentored countless investigators across Canada and internationally. She has served as a member or chair of guideline panels for ASCO, IASLC, and the National Comprehensive Cancer Network, and as an editor for leading journals. Her legacy is one of rigorous, practice-changing clinical science conducted with exceptional methodological standards and a patient-centered ethos.